ADVANCED MIC.DEV. DL-,01/ US0079031078 /
2024-04-26 9:56:55 PM | Chg. +3.880 | Volume | Bid10:01:49 PM | Ask10:01:49 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
147.200EUR | +2.71% | 32,372 Turnover: 4.74 mill. |
146.840Bid Size: 100 | 147.420Ask Size: 100 | 254.32 bill.EUR | - | - |
GlobeNewswire
04-25
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientif...
GlobeNewswire
04-18
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
GlobeNewswire
04-16
AMD Expands Commercial AI PC Portfolio to Deliver Leadership Performance Across Professional Mobile ...
GlobeNewswire
04-16
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire
04-16
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire
04-15
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...
GlobeNewswire
04-09
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice Pre...
GlobeNewswire
04-09
AMD Extends Leadership Adaptive SoC Portfolio with New Versal Series Gen 2 Devices Delivering End-to...
GlobeNewswire
04-06
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...